Clinical trial
An Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACM
NCT07602582 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACM
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- May 22, 2026
- Completion date
- September 30, 2029
- Enrollment
- 550 (estimated)
- Sites
- 59
Conditions
As the registry lists them; a condition with its own page is linked.